07:32:51 EDT Tue 16 Jul 2024
Enter Symbol
or Name

Login ID:

Q:AZN - ASTRAZENECA PLC SPON ADR EACH REP 0.50 ORD SHS - http://www.astrazeneca.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AZN - Q1.078.02·78.040.978.1224.115214    80.86  60.4707:11:53Jun 2515 min RT 2¢

Recent Trades - Last 10 of 14
Time ETExPriceChangeVolume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-06-25 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
2024-06-20 10:00U:AZNNews ReleasePancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
2024-06-17 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
2024-06-16 07:00U:AZNNews ReleaseCALQUENCE(TM) (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
2024-06-12 17:35U:AZNNews ReleaseFARXIGA approved in the US for the treatment of pediatric type-2 diabetes
2024-06-11 06:01U:AZNNews ReleaseSurging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development
2024-06-10 07:00U:AZNNews ReleaseTAGRISSO(TM) (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
2024-06-06 07:00U:AZNNews ReleaseI-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
2024-06-02 14:32U:AZNNews ReleaseTAGRISSO(TM) (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
2024-06-02 08:05U:AZNNews ReleaseIMFINZI(TM) (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
2024-06-02 08:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
2024-05-28 16:30U:AZNNews ReleaseCellectis Reports Financial Results for First Quarter 2024
2024-05-27 07:00U:AZNNews ReleaseDatopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
2024-05-23 07:00U:AZNNews ReleaseAstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
2024-05-22 07:00U:AZNNews ReleaseAstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
2024-05-21 02:00U:AZNNews ReleaseAstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
2024-05-19 17:17U:AZNNews ReleaseNew data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
2024-05-08 08:30U:AZNNews ReleaseMitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
2024-05-06 02:00U:AZNNews ReleaseCellectis Announces Completion of the Additional Equity Investment by AstraZeneca
2024-05-02 07:00U:AZNNews ReleaseCALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial